Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 4, 2013, Pages 1073-1082

  Wang, Shizhi ^a   Chen, Lulu ^a   Zhao, Qinghong ^b   Rong, Huan ^a   Wang, Meilin ^a   Gong, Weida ^c   Zhou, Jianwei ^a   Wu, Dongmei ^a   Zhang, Zhengdong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c Yixing Cancer Hospital   (China)

Author keywords

Gastric cancer; MDM2 SNP309; Survival; TP53 codon 72 polymorphism

Indexed keywords

ARGININE; CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; OXALIPLATIN; PROTEIN MDM2; PROTEIN P53; MDM2 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CODON; DISTANT METASTASIS; DRUG EFFECT; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MDM2 GENE; POSTOPERATIVE CARE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; ADJUVANT CHEMOTHERAPY; AGED; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; STOMACH TUMOR;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; CODON; FEMALE; FLUOROURACIL; GENES, P53; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; STOMACH NEOPLASMS;

MLCS; MLOWN;

EID: 84878844704     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2103-3     Document Type: Article

References (49)

1. Yang L (2006) Incidence and mortality of gastric cancer in China. World J Gastroenterol 12(1):17-20 (Pubitemid 43126077)
2. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ (2009) Gastric cancer. Lancet 374(9688):477-490. doi: 10.1016/S0140-6736(09)60617-6
3. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5(11):845-856. doi: 10.1038/nrc1739 (Pubitemid 41746029)
4. Shi Y, Hu Z, Wu C, Dai J, Li H, Dong J, Wang M, Miao X, Zhou Y, Lu F, Zhang H, Hu L, Jiang Y, Li Z, Chu M, Ma H, Chen J, Jin G, Tan W, Wu T, Zhang Z, Lin D, Shen H (2011) A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1. Nat Genet. doi: 10.1038/ng.978
5. Park SR, Kong SY, Nam BH, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH, Rhee J, Park YI, Kim NK (2011) CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer 104(7):1126-1134. doi: 10.1038/bjc.2011.24
6. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA, Wang WS, Etienne-Grimaldi MC, Wei Q (2011) ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 17(6):1632-1640. doi: 10.1158/1078-0432.CCR-10-2169
7. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408(6810):307-310. doi: 10.1038/35042675
8. Olivier M, Hussain SP, de Caron Fromentel C, Hainaut P, Harris CC (2004) TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 157:247-270
9. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A (2003) TP53 and gastric carcinoma: a review. Hum Mutat 21(3):258-270. doi: 10.1002/humu.10180 (Pubitemid 36292967)
10. Chua HW, Ng D, Choo S, Lum SS, Li H, Soh LY, Sabapathy K, Seow A (2010) Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 10:88. doi: 10.1186/1471-2407-10-88
11. Tang NP, Wu YM, Wang B, Ma J (2010) Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. Eur J Surg Oncol 36(5):431-438. doi: 10.1016/j.ejso.2010.03.010
12. Matakidou A, Eisen T, Houlston RS (2003) TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 18(4):377-385 (Pubitemid 36850206)
13. Francisco G, Menezes PR, Eluf-Neto J, Chammas R (2011) Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer 129(4):920-930. doi: 10.1002/ijc.25710
14. Huang ZH, Hua D, Li LH, Zhu JD (2008) Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. J Cancer Res Clin Oncol 134(10):1129-1134. doi: 10.1007/s00432-008-0380-8
15. Huang ZH, Hua D, Du X (2009) Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol 64(5):1001-1007. doi: 10.1007/s00280-009-0956-2
16. Kim JG, Sohn SK, Chae YS, Song HS, Kwon KY, Do YR, Kim MK, Lee KH, Hyun MS, Lee WS, Sohn CH, Jung JS, Kim GC, Chung HY, Yu W (2009) TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol 64(2):355-360. doi: 10.1007/s00280-008-0879-3
17. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69(7):1237-1245
18. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387(6630):296-299. doi: 10.1038/387296a0 (Pubitemid 27220766)
19. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119(5):591-602. doi: 10.1016/j.cell.2004.11.022 (Pubitemid 39535748)
20. Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R (2007) MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 13(14):4123-4129. doi: 10.1158/1078-0432.CCR-07-0609 (Pubitemid 47108171)
21. Huang CY, Su CT, Chu JS, Huang SP, Pu YS, Yang HY, Chung CJ, Wu CC, Hsueh YM (2011) The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area. Toxicol Appl Pharmacol. doi: 10.1016/j.taap.2011.09.018
22. Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger CM, Pasello M, Alberghini M, Ferrari C, Scotlandi K, Picci P, Serra M (2009) Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res 15(10):3550-3556. doi: 10.1158/1078-0432.CCR-08-2249
23. Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, Zhao D, Yu D, Liu J, Lin D (2007) Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 28(9):1996-2001. doi: 10.1093/carcin/bgm168 (Pubitemid 47500614)
24. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H (2006) MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 24(27):4434-4440. doi: 10.1200/JCO.2005.04.1459 (Pubitemid 46630981)
25. Wang M, Bai J, Tan Y, Wang S, Tian Y, Gong W, Zhou Y, Gao Y, Zhou J, Zhang Z (2011) Genetic variant in PSCA predicts survival of diffuse-type gastric cancer in a Chinese population. Int J Cancer 129(5):1207-1213. doi: 10.1002/ijc.25740
26. Greenland S, Rothman KJ (1998) Introduction to stratified analysis. Mod Epidemiol 2:253-279
27. Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-Naggar AK, Lozano G (2012) p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 21(6):793-806
28. Wang S, Li W, Xue Z, Lu Y, Narsinh K, Fan W, Li X, Bu Q, Wang F, Liang J, Wu K, Cao F (2012) Molecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin. Mol Carcinog. doi: 10.1002/mc.21930
29. El-Rifai W, Powell SM (2002) Molecular biology of gastric cancer. Semin Radiat Oncol 12(2):128-140. doi: 10.1053/srao.2002.30815 (Pubitemid 34522349)
30. Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, Varley JM (1998) Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17(9):1061-1068. doi: 10.1038/sj.onc.1202033 (Pubitemid 28444590)
31. Hrstka R, Coates PJ, Vojtesek B (2009) Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med 13(3):440-453. doi: 10.1111/j.1582-4934.2008.00634.x
32. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimaki A, von Smitten K, Aittomaki K, Heikkila P, Blomqvist C, Nevanlinna H (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11(14):5098-5103. doi: 10.1158/1078-0432.CCR-05-0173 (Pubitemid 41003693)
33. Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y (2005) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11(20):7328-7333. doi: 10.1158/1078-0432.CCR-05-0507 (Pubitemid 41507691)
34. Santos AM, Sousa H, Portela C, Pereira D, Pinto D, Catarino R, Rodrigues C, Araujo AP, Lopes C, Medeiros R (2006) TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 340(1):256-262. doi: 10.1016/j.bbrc.2005.11.176 (Pubitemid 41827674)
35. Galic V, Willner J, Wollan M, Garg R, Garcia R, Goff BA, Gray HJ, Swisher EM (2007) Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosom Cancer 46(3):239-247. doi: 10.1002/gcc.20407 (Pubitemid 46155319)
36. Han JY, Lee GK, Jang DH, Lee SY, Lee JS (2008) Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 113(4):799-807. doi: 10.1002/cncr.23668
37. Katkoori VR, Jia X, Shanmugam C, Wan W, Meleth S, Bumpers H, Grizzle WE, Manne U (2009) Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 15(7):2406-2416. doi: 10.1158/1078-0432.CCR-08-1719
38. Zhang ZW, Laurence NJ, Hollowood A, Newcomb P, Moorghen M, Gupta J, Feakins R, Farthing MJ, Alderson D, Holly J (2004) Prognostic value of TP53 codon 72 polymorphism in advanced gastric adenocarcinoma. Clin Cancer Res 10(1 Pt 1):131-135 (Pubitemid 38114171)
39. Godai TI, Suda T, Sugano N, Tsuchida K, Shiozawa M, Sekiguchi H, Sekiyama A, Yoshihara M, Matsukuma S, Sakuma Y, Tsuchiya E, Kameda Y, Akaike M, Miyagi Y (2009) Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer 9:420. doi: 10.1186/1471-2407-9-420
40. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33(3):357-365. doi: 10.1038/ng1093 (Pubitemid 36278852)
41. Kerr JF, Winterford CM, Harmon BV (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73(8):2013-2026 (Pubitemid 24107952)
42. Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, Magnusson OT, Gudjonsson SA, Sigurgeirsson B, Thorisdottir K, Ragnarsson R, Benediktsdottir KR, Nexo BA, Tjonneland A, Overvad K, Rudnai P, Gurzau E, Koppova K, Hemminki K, Corredera C, Fuentelsaz V, Grasa P, Navarrete S, Fuertes F, Garcia-Prats MD, Sanambrosio E, Panadero A, De Juan A, Garcia A, Rivera F, Planelles D, Soriano V, Requena C, Aben KK, van Rossum MM, Cremers RG, van Oort IM, van Spronsen DJ, Schalken JA, Peters WH, Helfand BT, Donovan JL, Hamdy FC, Badescu D, Codreanu O, Jinga M, Csiki IE, Constantinescu V, Badea P, Mates IN, Dinu DE, Constantin A, Mates D, Kristjansdottir S, Agnarsson BA, Jonsson E, Barkardottir RB, Einarsson GV, Sigurdsson F, Moller PH, Stefansson T, Valdimarsson T, Johannsson OT, Sigurdsson H, Jonsson T, Jonasson JG, Tryggvadottir L, Rice T, Hansen HM, Xiao Y, Lachance DH, BP ON, Kosel ML, Decker PA, Thorleifsson G, Johannsdottir H, Helgadottir HT, Sigurdsson A, Steinthorsdottir V, Lindblom A, Sandler RS, Keku TO, Banasik K, Jorgensen T, Witte DR, Hansen T, Pedersen O, Jinga V, Neal DE, Catalona WJ, Wrensch M, Wiencke J, Jenkins RB, Nagore E, Vogel U, Kiemeney LA, Kumar R, Mayordomo JI, Olafsson JH, Kong A, Thorsteinsdottir U, Rafnar T, Stefansson K (2011) A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet 43(11):1098-1103. doi: 10.1038/ng.926
43. Hof J, Krentz S, van Schewick C, Korner G, Shalapour S, Rhein P, Karawajew L, Ludwig WD, Seeger K, Henze G, von Stackelberg A, Hagemeier C, Eckert C, Kirschner-Schwabe R (2011) Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol 29(23):3185-3193. doi: 10.1200/JCO.2011.34.8144
44. Blumrich A, Zapatka M, Brueckner LM, Zheglo D, Schwab M, Savelyeva L (2011) The FRA2C common fragile site maps to the borders of MYCN amplicons in neuroblastoma and is associated with gross chromosomal rearrangements in different cancers. Hum Mol Genet 20(8):1488-1501. doi: 10.1093/hmg/ddr027
45. Rakyan VK, Down TA, Balding DJ, Beck S (2011) Epigenome-wide association studies for common human diseases. Nat Rev Genet 12(8):529-541. doi: 10.1038/nrg3000
46. Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ (2011) A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann oncol: off J Eur Soc Med Oncol/ESMO 22(1):104-109. doi: 10.1093/annonc/mdq315
47. Sun Q, Gu H, Zeng Y, Xia Y, Wang Y, Jing Y, Yang L, Wang B (2010) Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expression. Cancer Sci 101(10):2241-2247. doi: 10.1111/j.1349-7006.2010.01667.x
48. Gschwend JE, Dahm P, Fair WR (2002) Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. Eur Urol 41(4):440-448 (Pubitemid 35333942)
49. Winder T, Zhang W, Yang D, Ning Y, Bohanes P, Gerger A, Wilson PM, Pohl A, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ (2010) Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. Clin Cancer Res 16(22):5591-5602. doi: 10.1158/1078-0432. CCR-10-2092